All In Biotech

Drug Trial Radar · NCT00389909

Dosing Chart for Calculating the First Dose of Doxapram in Premature Infants

Evaluation of Dosing Chart Taking Into Account Age and Gender for Calculating the First Dose of Doxapram in Premature Infants

Last checked: Nov 20, 2026Latest source record: Feb 27, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

85

Actual

Start

Nov 2006

Primary completion

Nov 2010

Study completion Nov 2010

Sponsor

Lead sponsor
Jean Michel HascoetAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 19, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 1 week, up to 3 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Doxapram is used to stimulate respiration. For a given dose, the fluctuations in concentrations observed in infants' blood may be wide, leading to a risk of lack of efficacy or of toxic effects. Two factors are linked to these fluctuations: age and gender. The aim of this study is to compare a dosage regimen based only on patient's weight, to another one using a dosing chart taking into account weight, age and gender.

Conditions

  • Premature Infants
  • Apnea

Interventions

  • DoxapramDrug

    Dosing comparison between fixed scheduled and sex related dosage. Dosing related to weight only versus chart taking into account weight, age and gender.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Plasma level of Doxapram and its active metabolite (ketodoxapram) at 48 hours after the onset of treatment.Time frame: 48 Hours

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Maternite Regionale Universitaire

    Nancy, France

  • Hopital des Enfants

    Toulouse, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.